nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2A—myenteric nerve plexus—colon cancer	0.0349	0.175	CbGeAlD
Atomoxetine—HTR2A—vein—colon cancer	0.0225	0.113	CbGeAlD
Atomoxetine—NPY1R—renal system—colon cancer	0.0158	0.079	CbGeAlD
Atomoxetine—HTR1B—blood vessel—colon cancer	0.0148	0.0743	CbGeAlD
Atomoxetine—HTR1D—blood vessel—colon cancer	0.0144	0.0719	CbGeAlD
Atomoxetine—NPY1R—vagina—colon cancer	0.0114	0.0573	CbGeAlD
Atomoxetine—NPY1R—liver—colon cancer	0.00965	0.0483	CbGeAlD
Atomoxetine—HTR2A—endothelium—colon cancer	0.00774	0.0387	CbGeAlD
Atomoxetine—NPY1R—lymph node—colon cancer	0.0074	0.037	CbGeAlD
Atomoxetine—HTR2A—blood vessel—colon cancer	0.00714	0.0357	CbGeAlD
Atomoxetine—SLC6A4—digestive system—colon cancer	0.00499	0.025	CbGeAlD
Atomoxetine—HTR2A—embryo—colon cancer	0.00426	0.0213	CbGeAlD
Atomoxetine—CYP2C19—digestive system—colon cancer	0.00414	0.0207	CbGeAlD
Atomoxetine—Weight decreased—Irinotecan—colon cancer	0.00409	0.00525	CcSEcCtD
Atomoxetine—Sleep disorder—Capecitabine—colon cancer	0.00405	0.00519	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00403	0.00516	CcSEcCtD
Atomoxetine—Bone disorder—Methotrexate—colon cancer	0.00398	0.0051	CcSEcCtD
Atomoxetine—Hepatic failure—Capecitabine—colon cancer	0.0039	0.005	CcSEcCtD
Atomoxetine—Infestation NOS—Fluorouracil—colon cancer	0.00386	0.00495	CcSEcCtD
Atomoxetine—Infestation—Fluorouracil—colon cancer	0.00386	0.00495	CcSEcCtD
Atomoxetine—Libido decreased—Capecitabine—colon cancer	0.00378	0.00484	CcSEcCtD
Atomoxetine—Conjunctivitis—Fluorouracil—colon cancer	0.00376	0.00481	CcSEcCtD
Atomoxetine—Hot flush—Capecitabine—colon cancer	0.00375	0.0048	CcSEcCtD
Atomoxetine—Menopausal symptoms—Capecitabine—colon cancer	0.00371	0.00476	CcSEcCtD
Atomoxetine—Hypoaesthesia—Vincristine—colon cancer	0.0037	0.00474	CcSEcCtD
Atomoxetine—Hallucination—Vincristine—colon cancer	0.0037	0.00474	CcSEcCtD
Atomoxetine—Thirst—Capecitabine—colon cancer	0.00368	0.00472	CcSEcCtD
Atomoxetine—Urinary tract disorder—Vincristine—colon cancer	0.00367	0.00471	CcSEcCtD
Atomoxetine—CYP2C19—vagina—colon cancer	0.00365	0.0183	CbGeAlD
Atomoxetine—Urethral disorder—Vincristine—colon cancer	0.00365	0.00467	CcSEcCtD
Atomoxetine—Sinusitis—Fluorouracil—colon cancer	0.00362	0.00465	CcSEcCtD
Atomoxetine—Lethargy—Capecitabine—colon cancer	0.00358	0.00458	CcSEcCtD
Atomoxetine—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00348	0.00445	CcSEcCtD
Atomoxetine—HTR2A—epithelium—colon cancer	0.00347	0.0174	CbGeAlD
Atomoxetine—Cardiac disorder—Vincristine—colon cancer	0.00345	0.00442	CcSEcCtD
Atomoxetine—Hypoaesthesia—Fluorouracil—colon cancer	0.00345	0.00442	CcSEcCtD
Atomoxetine—Angiopathy—Vincristine—colon cancer	0.00337	0.00432	CcSEcCtD
Atomoxetine—Flushing—Irinotecan—colon cancer	0.00336	0.00431	CcSEcCtD
Atomoxetine—Cardiac disorder—Irinotecan—colon cancer	0.00336	0.00431	CcSEcCtD
Atomoxetine—Mediastinal disorder—Vincristine—colon cancer	0.00335	0.00429	CcSEcCtD
Atomoxetine—HTR2A—smooth muscle tissue—colon cancer	0.00335	0.0168	CbGeAlD
Atomoxetine—Irritability—Capecitabine—colon cancer	0.00334	0.00429	CcSEcCtD
Atomoxetine—Urinary retention—Capecitabine—colon cancer	0.00333	0.00427	CcSEcCtD
Atomoxetine—Mood swings—Capecitabine—colon cancer	0.00332	0.00425	CcSEcCtD
Atomoxetine—Angiopathy—Irinotecan—colon cancer	0.00329	0.00421	CcSEcCtD
Atomoxetine—Coma—Methotrexate—colon cancer	0.00328	0.00421	CcSEcCtD
Atomoxetine—Reboxetine—ABCB1—colon cancer	0.00328	0.165	CrCbGaD
Atomoxetine—Mediastinal disorder—Irinotecan—colon cancer	0.00326	0.00418	CcSEcCtD
Atomoxetine—Mental disorder—Vincristine—colon cancer	0.00326	0.00418	CcSEcCtD
Atomoxetine—Chills—Irinotecan—colon cancer	0.00325	0.00416	CcSEcCtD
Atomoxetine—HTR2A—renal system—colon cancer	0.00322	0.0161	CbGeAlD
Atomoxetine—Abdominal pain upper—Capecitabine—colon cancer	0.0032	0.0041	CcSEcCtD
Atomoxetine—Breast disorder—Capecitabine—colon cancer	0.00317	0.00406	CcSEcCtD
Atomoxetine—Nasopharyngitis—Capecitabine—colon cancer	0.00313	0.00402	CcSEcCtD
Atomoxetine—Back pain—Vincristine—colon cancer	0.00313	0.00401	CcSEcCtD
Atomoxetine—Flatulence—Irinotecan—colon cancer	0.00311	0.00398	CcSEcCtD
Atomoxetine—CYP2C19—liver—colon cancer	0.00308	0.0154	CbGeAlD
Atomoxetine—Back pain—Irinotecan—colon cancer	0.00305	0.00391	CcSEcCtD
Atomoxetine—Muscle spasms—Irinotecan—colon cancer	0.00303	0.00388	CcSEcCtD
Atomoxetine—Influenza—Capecitabine—colon cancer	0.00303	0.00388	CcSEcCtD
Atomoxetine—Protriptyline—ABCB1—colon cancer	0.00301	0.151	CrCbGaD
Atomoxetine—CYP3A4—renal system—colon cancer	0.00298	0.0149	CbGeAlD
Atomoxetine—Agitation—Vincristine—colon cancer	0.00297	0.00381	CcSEcCtD
Atomoxetine—Sweating increased—Capecitabine—colon cancer	0.00295	0.00378	CcSEcCtD
Atomoxetine—CYP2D6—renal system—colon cancer	0.00294	0.0147	CbGeAlD
Atomoxetine—Vertigo—Vincristine—colon cancer	0.00291	0.00373	CcSEcCtD
Atomoxetine—Abdominal discomfort—Capecitabine—colon cancer	0.0029	0.00372	CcSEcCtD
Atomoxetine—Hepatic failure—Methotrexate—colon cancer	0.0029	0.00372	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—colon cancer	0.00288	0.145	CrCbGaD
Atomoxetine—Vision blurred—Fluorouracil—colon cancer	0.00285	0.00365	CcSEcCtD
Atomoxetine—Vertigo—Irinotecan—colon cancer	0.00283	0.00363	CcSEcCtD
Atomoxetine—Dysuria—Capecitabine—colon cancer	0.00283	0.00363	CcSEcCtD
Atomoxetine—Syncope—Irinotecan—colon cancer	0.00283	0.00362	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Capecitabine—colon cancer	0.00281	0.00361	CcSEcCtD
Atomoxetine—Convulsion—Vincristine—colon cancer	0.0028	0.00359	CcSEcCtD
Atomoxetine—Loss of consciousness—Irinotecan—colon cancer	0.00277	0.00355	CcSEcCtD
Atomoxetine—Myalgia—Vincristine—colon cancer	0.00276	0.00353	CcSEcCtD
Atomoxetine—Cough—Irinotecan—colon cancer	0.00275	0.00353	CcSEcCtD
Atomoxetine—Weight decreased—Capecitabine—colon cancer	0.00274	0.00351	CcSEcCtD
Atomoxetine—Infestation NOS—Capecitabine—colon cancer	0.0027	0.00346	CcSEcCtD
Atomoxetine—Infestation—Capecitabine—colon cancer	0.0027	0.00346	CcSEcCtD
Atomoxetine—Depression—Capecitabine—colon cancer	0.00269	0.00345	CcSEcCtD
Atomoxetine—Lethargy—Methotrexate—colon cancer	0.00266	0.00341	CcSEcCtD
Atomoxetine—HTR2A—digestive system—colon cancer	0.00264	0.0132	CbGeAlD
Atomoxetine—Infection—Vincristine—colon cancer	0.00262	0.00336	CcSEcCtD
Atomoxetine—Conjunctivitis—Capecitabine—colon cancer	0.00262	0.00336	CcSEcCtD
Atomoxetine—Convulsion—Fluorouracil—colon cancer	0.00262	0.00335	CcSEcCtD
Atomoxetine—Nervous system disorder—Vincristine—colon cancer	0.00259	0.00332	CcSEcCtD
Atomoxetine—Myalgia—Fluorouracil—colon cancer	0.00257	0.00329	CcSEcCtD
Atomoxetine—Chest pain—Fluorouracil—colon cancer	0.00257	0.00329	CcSEcCtD
Atomoxetine—Infection—Irinotecan—colon cancer	0.00256	0.00328	CcSEcCtD
Atomoxetine—Hyperhidrosis—Vincristine—colon cancer	0.00255	0.00327	CcSEcCtD
Atomoxetine—Shock—Irinotecan—colon cancer	0.00253	0.00324	CcSEcCtD
Atomoxetine—Nervous system disorder—Irinotecan—colon cancer	0.00252	0.00323	CcSEcCtD
Atomoxetine—Anorexia—Vincristine—colon cancer	0.00252	0.00323	CcSEcCtD
Atomoxetine—SLC6A2—lymph node—colon cancer	0.00251	0.0126	CbGeAlD
Atomoxetine—Irritability—Methotrexate—colon cancer	0.00249	0.00319	CcSEcCtD
Atomoxetine—Hyperhidrosis—Irinotecan—colon cancer	0.00249	0.00319	CcSEcCtD
Atomoxetine—Mood swings—Methotrexate—colon cancer	0.00247	0.00317	CcSEcCtD
Atomoxetine—Anorexia—Irinotecan—colon cancer	0.00245	0.00314	CcSEcCtD
Atomoxetine—Infection—Fluorouracil—colon cancer	0.00245	0.00314	CcSEcCtD
Atomoxetine—CYP3A4—digestive system—colon cancer	0.00245	0.0122	CbGeAlD
Atomoxetine—Nervous system disorder—Fluorouracil—colon cancer	0.00242	0.0031	CcSEcCtD
Atomoxetine—Hypoaesthesia—Capecitabine—colon cancer	0.00241	0.00309	CcSEcCtD
Atomoxetine—CYP2D6—digestive system—colon cancer	0.00241	0.0121	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Vincristine—colon cancer	0.00241	0.00308	CcSEcCtD
Atomoxetine—Tachycardia—Fluorouracil—colon cancer	0.00241	0.00308	CcSEcCtD
Atomoxetine—Urinary tract disorder—Capecitabine—colon cancer	0.00239	0.00307	CcSEcCtD
Atomoxetine—Insomnia—Vincristine—colon cancer	0.00239	0.00306	CcSEcCtD
Atomoxetine—Urethral disorder—Capecitabine—colon cancer	0.00238	0.00304	CcSEcCtD
Atomoxetine—Paraesthesia—Vincristine—colon cancer	0.00237	0.00304	CcSEcCtD
Atomoxetine—Breast disorder—Methotrexate—colon cancer	0.00236	0.00302	CcSEcCtD
Atomoxetine—Anorexia—Fluorouracil—colon cancer	0.00235	0.00301	CcSEcCtD
Atomoxetine—HTR2A—vagina—colon cancer	0.00233	0.0117	CbGeAlD
Atomoxetine—Insomnia—Irinotecan—colon cancer	0.00233	0.00298	CcSEcCtD
Atomoxetine—Paraesthesia—Irinotecan—colon cancer	0.00231	0.00296	CcSEcCtD
Atomoxetine—Decreased appetite—Vincristine—colon cancer	0.0023	0.00294	CcSEcCtD
Atomoxetine—Somnolence—Irinotecan—colon cancer	0.00229	0.00293	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vincristine—colon cancer	0.00228	0.00292	CcSEcCtD
Atomoxetine—Fatigue—Vincristine—colon cancer	0.00228	0.00292	CcSEcCtD
Atomoxetine—Dyspepsia—Irinotecan—colon cancer	0.00226	0.0029	CcSEcCtD
Atomoxetine—Pain—Vincristine—colon cancer	0.00226	0.0029	CcSEcCtD
Atomoxetine—Constipation—Vincristine—colon cancer	0.00226	0.0029	CcSEcCtD
Atomoxetine—Cardiac disorder—Capecitabine—colon cancer	0.00225	0.00288	CcSEcCtD
Atomoxetine—Flushing—Capecitabine—colon cancer	0.00225	0.00288	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00225	0.00288	CcSEcCtD
Atomoxetine—Decreased appetite—Irinotecan—colon cancer	0.00224	0.00287	CcSEcCtD
Atomoxetine—Insomnia—Fluorouracil—colon cancer	0.00223	0.00286	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Irinotecan—colon cancer	0.00222	0.00285	CcSEcCtD
Atomoxetine—Fatigue—Irinotecan—colon cancer	0.00222	0.00284	CcSEcCtD
Atomoxetine—Paraesthesia—Fluorouracil—colon cancer	0.00221	0.00284	CcSEcCtD
Atomoxetine—Pain—Irinotecan—colon cancer	0.0022	0.00282	CcSEcCtD
Atomoxetine—Constipation—Irinotecan—colon cancer	0.0022	0.00282	CcSEcCtD
Atomoxetine—Angiopathy—Capecitabine—colon cancer	0.0022	0.00282	CcSEcCtD
Atomoxetine—Somnolence—Fluorouracil—colon cancer	0.00219	0.00281	CcSEcCtD
Atomoxetine—Mediastinal disorder—Capecitabine—colon cancer	0.00218	0.0028	CcSEcCtD
Atomoxetine—Chills—Capecitabine—colon cancer	0.00217	0.00279	CcSEcCtD
Atomoxetine—Dyspepsia—Fluorouracil—colon cancer	0.00217	0.00278	CcSEcCtD
Atomoxetine—Abdominal discomfort—Methotrexate—colon cancer	0.00216	0.00277	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vincristine—colon cancer	0.00216	0.00277	CcSEcCtD
Atomoxetine—Decreased appetite—Fluorouracil—colon cancer	0.00214	0.00275	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00213	0.00273	CcSEcCtD
Atomoxetine—Mental disorder—Capecitabine—colon cancer	0.00212	0.00272	CcSEcCtD
Atomoxetine—Feeling abnormal—Irinotecan—colon cancer	0.00212	0.00272	CcSEcCtD
Atomoxetine—Malnutrition—Capecitabine—colon cancer	0.00211	0.0027	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—colon cancer	0.00211	0.0027	CcSEcCtD
Atomoxetine—Pain—Fluorouracil—colon cancer	0.00211	0.0027	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Irinotecan—colon cancer	0.0021	0.0027	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Methotrexate—colon cancer	0.0021	0.00268	CcSEcCtD
Atomoxetine—Abdominal pain—Vincristine—colon cancer	0.00209	0.00268	CcSEcCtD
Atomoxetine—Body temperature increased—Vincristine—colon cancer	0.00209	0.00268	CcSEcCtD
Atomoxetine—Flatulence—Capecitabine—colon cancer	0.00208	0.00266	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—colon cancer	0.00208	0.00266	CcSEcCtD
Atomoxetine—Dysgeusia—Capecitabine—colon cancer	0.00207	0.00265	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—colon cancer	0.00206	0.103	CrCbGaD
Atomoxetine—Back pain—Capecitabine—colon cancer	0.00204	0.00262	CcSEcCtD
Atomoxetine—Abdominal pain—Irinotecan—colon cancer	0.00203	0.00261	CcSEcCtD
Atomoxetine—Body temperature increased—Irinotecan—colon cancer	0.00203	0.00261	CcSEcCtD
Atomoxetine—Feeling abnormal—Fluorouracil—colon cancer	0.00203	0.0026	CcSEcCtD
Atomoxetine—Muscle spasms—Capecitabine—colon cancer	0.00203	0.0026	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—colon cancer	0.00201	0.00258	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—colon cancer	0.00201	0.00258	CcSEcCtD
Atomoxetine—Depression—Methotrexate—colon cancer	0.002	0.00257	CcSEcCtD
Atomoxetine—Vision blurred—Capecitabine—colon cancer	0.00199	0.00255	CcSEcCtD
Atomoxetine—Tremor—Capecitabine—colon cancer	0.00198	0.00253	CcSEcCtD
Atomoxetine—HTR2A—liver—colon cancer	0.00197	0.00985	CbGeAlD
Atomoxetine—Urticaria—Fluorouracil—colon cancer	0.00196	0.00251	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—colon cancer	0.00195	0.0025	CcSEcCtD
Atomoxetine—Body temperature increased—Fluorouracil—colon cancer	0.00195	0.0025	CcSEcCtD
Atomoxetine—Maprotiline—ABCB1—colon cancer	0.00192	0.0964	CrCbGaD
Atomoxetine—Vertigo—Capecitabine—colon cancer	0.0019	0.00243	CcSEcCtD
Atomoxetine—Asthenia—Vincristine—colon cancer	0.0019	0.00243	CcSEcCtD
Atomoxetine—Syncope—Capecitabine—colon cancer	0.00189	0.00242	CcSEcCtD
Atomoxetine—Palpitations—Capecitabine—colon cancer	0.00186	0.00239	CcSEcCtD
Atomoxetine—Loss of consciousness—Capecitabine—colon cancer	0.00185	0.00238	CcSEcCtD
Atomoxetine—Asthenia—Irinotecan—colon cancer	0.00185	0.00237	CcSEcCtD
Atomoxetine—Cough—Capecitabine—colon cancer	0.00184	0.00236	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—colon cancer	0.00183	0.092	CrCbGaD
Atomoxetine—CYP3A4—liver—colon cancer	0.00182	0.00912	CbGeAlD
Atomoxetine—Diarrhoea—Vincristine—colon cancer	0.00181	0.00232	CcSEcCtD
Atomoxetine—Myalgia—Capecitabine—colon cancer	0.0018	0.0023	CcSEcCtD
Atomoxetine—Arthralgia—Capecitabine—colon cancer	0.0018	0.0023	CcSEcCtD
Atomoxetine—Chest pain—Capecitabine—colon cancer	0.0018	0.0023	CcSEcCtD
Atomoxetine—CYP2D6—liver—colon cancer	0.00179	0.00898	CbGeAlD
Atomoxetine—Anxiety—Capecitabine—colon cancer	0.00179	0.00229	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00178	0.00229	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—colon cancer	0.00178	0.00228	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—colon cancer	0.00177	0.00227	CcSEcCtD
Atomoxetine—Diarrhoea—Irinotecan—colon cancer	0.00176	0.00226	CcSEcCtD
Atomoxetine—Dry mouth—Capecitabine—colon cancer	0.00176	0.00225	CcSEcCtD
Atomoxetine—Dizziness—Vincristine—colon cancer	0.00175	0.00224	CcSEcCtD
Atomoxetine—Pruritus—Fluorouracil—colon cancer	0.00174	0.00223	CcSEcCtD
Atomoxetine—Infection—Capecitabine—colon cancer	0.00171	0.00219	CcSEcCtD
Atomoxetine—Dizziness—Irinotecan—colon cancer	0.0017	0.00218	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—colon cancer	0.0017	0.0854	CrCbGaD
Atomoxetine—Shock—Capecitabine—colon cancer	0.00169	0.00217	CcSEcCtD
Atomoxetine—Nervous system disorder—Capecitabine—colon cancer	0.00169	0.00216	CcSEcCtD
Atomoxetine—Diarrhoea—Fluorouracil—colon cancer	0.00169	0.00216	CcSEcCtD
Atomoxetine—Tachycardia—Capecitabine—colon cancer	0.00168	0.00215	CcSEcCtD
Atomoxetine—Vomiting—Vincristine—colon cancer	0.00168	0.00215	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—colon cancer	0.00167	0.00215	CcSEcCtD
Atomoxetine—Skin disorder—Capecitabine—colon cancer	0.00167	0.00214	CcSEcCtD
Atomoxetine—Rash—Vincristine—colon cancer	0.00167	0.00213	CcSEcCtD
Atomoxetine—Hyperhidrosis—Capecitabine—colon cancer	0.00166	0.00213	CcSEcCtD
Atomoxetine—Dermatitis—Vincristine—colon cancer	0.00166	0.00213	CcSEcCtD
Atomoxetine—Headache—Vincristine—colon cancer	0.00166	0.00212	CcSEcCtD
Atomoxetine—Anorexia—Capecitabine—colon cancer	0.00164	0.0021	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—colon cancer	0.00164	0.0021	CcSEcCtD
Atomoxetine—Vomiting—Irinotecan—colon cancer	0.00164	0.0021	CcSEcCtD
Atomoxetine—Dizziness—Fluorouracil—colon cancer	0.00163	0.00209	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—colon cancer	0.00163	0.00208	CcSEcCtD
Atomoxetine—Rash—Irinotecan—colon cancer	0.00162	0.00208	CcSEcCtD
Atomoxetine—Dermatitis—Irinotecan—colon cancer	0.00162	0.00208	CcSEcCtD
Atomoxetine—Chills—Methotrexate—colon cancer	0.00162	0.00207	CcSEcCtD
Atomoxetine—Headache—Irinotecan—colon cancer	0.00161	0.00207	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—colon cancer	0.00158	0.00203	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—colon cancer	0.00157	0.00201	CcSEcCtD
Atomoxetine—Nausea—Vincristine—colon cancer	0.00157	0.00201	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00157	0.00201	CcSEcCtD
Atomoxetine—Vomiting—Fluorouracil—colon cancer	0.00157	0.00201	CcSEcCtD
Atomoxetine—Insomnia—Capecitabine—colon cancer	0.00156	0.002	CcSEcCtD
Atomoxetine—Rash—Fluorouracil—colon cancer	0.00155	0.00199	CcSEcCtD
Atomoxetine—Dermatitis—Fluorouracil—colon cancer	0.00155	0.00199	CcSEcCtD
Atomoxetine—Paraesthesia—Capecitabine—colon cancer	0.00155	0.00198	CcSEcCtD
Atomoxetine—Headache—Fluorouracil—colon cancer	0.00154	0.00198	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—colon cancer	0.00154	0.00197	CcSEcCtD
Atomoxetine—Nausea—Irinotecan—colon cancer	0.00153	0.00196	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—colon cancer	0.00152	0.00195	CcSEcCtD
Atomoxetine—Dyspepsia—Capecitabine—colon cancer	0.00152	0.00194	CcSEcCtD
Atomoxetine—Decreased appetite—Capecitabine—colon cancer	0.0015	0.00192	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Capecitabine—colon cancer	0.00149	0.00191	CcSEcCtD
Atomoxetine—Fatigue—Capecitabine—colon cancer	0.00148	0.0019	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—colon cancer	0.00148	0.0019	CcSEcCtD
Atomoxetine—Constipation—Capecitabine—colon cancer	0.00147	0.00189	CcSEcCtD
Atomoxetine—Pain—Capecitabine—colon cancer	0.00147	0.00189	CcSEcCtD
Atomoxetine—Nausea—Fluorouracil—colon cancer	0.00146	0.00188	CcSEcCtD
Atomoxetine—Feeling abnormal—Capecitabine—colon cancer	0.00142	0.00182	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—colon cancer	0.00141	0.00181	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Capecitabine—colon cancer	0.00141	0.0018	CcSEcCtD
Atomoxetine—Cough—Methotrexate—colon cancer	0.00137	0.00176	CcSEcCtD
Atomoxetine—Urticaria—Capecitabine—colon cancer	0.00137	0.00175	CcSEcCtD
Atomoxetine—Body temperature increased—Capecitabine—colon cancer	0.00136	0.00174	CcSEcCtD
Atomoxetine—Abdominal pain—Capecitabine—colon cancer	0.00136	0.00174	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—colon cancer	0.00136	0.00174	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—colon cancer	0.00134	0.00171	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—colon cancer	0.00134	0.00171	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—colon cancer	0.00134	0.00171	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00133	0.0017	CcSEcCtD
Atomoxetine—Infection—Methotrexate—colon cancer	0.00127	0.00163	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—colon cancer	0.00126	0.00161	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—colon cancer	0.00125	0.063	CrCbGaD
Atomoxetine—Skin disorder—Methotrexate—colon cancer	0.00125	0.0016	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—colon cancer	0.00124	0.00159	CcSEcCtD
Atomoxetine—Asthenia—Capecitabine—colon cancer	0.00124	0.00158	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—colon cancer	0.00122	0.00157	CcSEcCtD
Atomoxetine—Pruritus—Capecitabine—colon cancer	0.00122	0.00156	CcSEcCtD
Atomoxetine—Diarrhoea—Capecitabine—colon cancer	0.00118	0.00151	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00117	0.0015	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—colon cancer	0.00116	0.00149	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—colon cancer	0.00115	0.00148	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—colon cancer	0.00114	0.00146	CcSEcCtD
Atomoxetine—Dizziness—Capecitabine—colon cancer	0.00114	0.00146	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—colon cancer	0.00113	0.00145	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—colon cancer	0.00111	0.00143	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—colon cancer	0.00111	0.00142	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—colon cancer	0.00111	0.00142	CcSEcCtD
Atomoxetine—Pain—Methotrexate—colon cancer	0.0011	0.0014	CcSEcCtD
Atomoxetine—Vomiting—Capecitabine—colon cancer	0.00109	0.0014	CcSEcCtD
Atomoxetine—Rash—Capecitabine—colon cancer	0.00109	0.00139	CcSEcCtD
Atomoxetine—Dermatitis—Capecitabine—colon cancer	0.00108	0.00139	CcSEcCtD
Atomoxetine—Headache—Capecitabine—colon cancer	0.00108	0.00138	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—colon cancer	0.00106	0.00135	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—colon cancer	0.00105	0.00134	CcSEcCtD
Atomoxetine—Methadone—ABCB1—colon cancer	0.00103	0.0517	CrCbGaD
Atomoxetine—Nausea—Capecitabine—colon cancer	0.00102	0.00131	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—colon cancer	0.00102	0.00131	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—colon cancer	0.00101	0.0013	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—colon cancer	0.00101	0.0013	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—colon cancer	0.00095	0.0477	CrCbGaD
Atomoxetine—Asthenia—Methotrexate—colon cancer	0.00092	0.00118	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—colon cancer	0.000907	0.00116	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—colon cancer	0.000877	0.00112	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—colon cancer	0.000848	0.00109	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—colon cancer	0.000815	0.00104	CcSEcCtD
Atomoxetine—Rash—Methotrexate—colon cancer	0.000808	0.00104	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—colon cancer	0.000808	0.00103	CcSEcCtD
Atomoxetine—Headache—Methotrexate—colon cancer	0.000803	0.00103	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—colon cancer	0.000761	0.000976	CcSEcCtD
